Legal Representation
Attorney
ADRIENNE L. WHITE
USPTO Deadlines
Application History
40 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Apr 11, 2022 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
Apr 11, 2022 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
Sep 15, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Sep 14, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
Sep 14, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Sep 7, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Sep 7, 2021 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
Mar 9, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Jan 12, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Jan 12, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Dec 23, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Dec 3, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Dec 3, 2020 | EXPT | T | EXPARTE APPEAL TERMINATED | Loading... |
Nov 3, 2020 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY | Loading... |
Sep 12, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Sep 12, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Sep 3, 2020 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
Aug 31, 2020 | CNCF | S | ACTION CONTINUING FINAL - COMPLETED | Loading... |
Aug 31, 2020 | GECD | O | ACTION DENYING REQ FOR RECON E-MAILED | Loading... |
Aug 31, 2020 | GEA1 | O | NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED | Loading... |
Aug 4, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Aug 4, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Aug 3, 2020 | EXAF | T | EXPARTE APPEAL RECEIVED AT TTAB | Loading... |
Aug 3, 2020 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY | Loading... |
Aug 3, 2020 | EXPI | T | EX PARTE APPEAL-INSTITUTED | Loading... |
Aug 3, 2020 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
Feb 3, 2020 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
Feb 3, 2020 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
Feb 3, 2020 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
Dec 30, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
Dec 30, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Dec 30, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Dec 9, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Jun 7, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Jun 7, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Jun 7, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
May 31, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Apr 9, 2019 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
Apr 7, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Mar 23, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical and veterinary preparations, namely, cellular preparations for the treatment of tumours/neoplastic diseases, hematological tumors, more specifically leukemias or lymphomkas, solid tumors; Pharmaceutical T-cell preparations and dendritic cell preparations for the treatment of cancer and use in immunotherapy; medical compositions in the nature of pharmaceutical preparations for the treatment of hematological and solid tumors, tumor precursors; Test kits for diagnostic preparations for medical purposes for determining the type and/or existence of a tumor in a patient consisting primarily of soluble T-cell receptors; test kits for diagnostic preparations for medical purposes for determining the type and/or existence of a tumor in a patient consisting primarily of genetically modified cells; Test kits for diagnostic preparations for medical purposes for determining the type/existence of a tumor in a patient consisting of a composition of antibodies, soluble T-cell receptors and genetically modified cells; Diagnostic and therapeutic preparations for medical purposes being mixtures of therapeutically active cells in a suitable medium, in particular produced using molecular biological, biotechnological and genetic methods
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Services in molecular biology, in particular research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological and genetic methods, and in the field of screening for compounds with pharmaceutical properties; Development of test methods and test kits; Development of adoptive T cell therapy; Development of DC vaccines; Development of cellular tumour therapy; Development of tumour markers; Development of diagnostic and therapeutic antibodies
First Use Anywhere:
0
First Use in Commerce:
0
Class 044
Cell analyses in the nature of medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical and veterinary medical services, in particular extracting of blood and/or tissue samples and analysis and evaluation relating thereto; Individualized medicine in the nature of medical services; medical services specifically, development of treatment plans for the treatment of tumors and/or neoplastic diseases, hematopoietic tumors, solid tumors; physical therapy adapted for individual patients
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of the wording "MEDIGENE" in stylized script, where the letter "I" is comprised of two oval shapes.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
042
044